Indoco RemediesQ2 FY24

Indoco Remedies Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹224.98Market Cap: ₹2.1K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

Yes

Order

N/A

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 3
  • Domestic business growth: Confident of achieving 14%-16% growth in H2 FY24, driven by both seasonal products and sub-chronic therapies like stomatology and ophthalmics.
  • Europe business: Maintaining guidance of Rs. 375-380 crores for FY24 with expectation of order normalization after recent overstocking issues.
  • US business: Expect continued strong performance with sustainable profit share from products like Brinzolamide in Q3 and Q4.
  • Emerging markets: Significant growth observed (71.6% rise in Q2 revenues), expected to continue.
  • API business: Strong growth (95.6% increase in Q2), indicating robust volume expansion.
  • Overall company outlook: Well-positioned with ongoing capacity expansions, new product launches, ANDA filings, and improved operational efficiencies to support volume and value growth.

See what Indoco Remedies management said on margin guidance — free account, 30 seconds.

Fundraise plans

Yes
  • The transcript does not explicitly mention any current or planned fundraising through debt or equity.
  • The company has taken an ECB (External Commercial Borrowing) for acquisition-related funding, with the drawdown temporarily parked for future use.
  • Debt repayment schedule is outlined, with term loan repayments of approximately Rs. 24 crores in H2 FY24 and Rs. 45-50 crores annually over the next two years, indicating planned debt reduction.
  • Management mentioned they have not confirmed any M&A but are always looking for opportunities, suggesting potential future strategic investments.
  • No direct indication of fresh equity fundraising was provided during the call.

See what Indoco Remedies management said on order book — free account, 30 seconds.

Capex plans

Yes
- Recent expansions include a Waluj plant expansion to meet volume demand from emerging and Indian markets. - Upgrades at the API facility in Patalganga, including a larger quality control laboratory. - Contemplation of a new business in pharmacovigilance via AnaCipher CRO in Hyderabad. - Ongoing IT projects across HR, operations, sales, and quality assurance at manufacturing sites. - Initiatives underway to increase batch size, improve yield, and reduce overheads especially related to human capital. - Greenfield and Brownfield expansion programs are underway at multiple sites. - Recent drawdown of an ECB (External Commercial Borrowing) to cover cash requirements for acquisition-related purposes, funds currently parked temporarily for future use. - While no concrete M&A is currently in execution, the company is actively scouting for good brands in India and quality facilities internationally. - Investments aimed at improving efficiency and competitiveness of products. Overall, the company is actively investing in capacity, capabilities, and potential strategic acquisitions.

Track Indoco Remedies — get its next earnings analysis in your feed

How does Indoco Remedies rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisIndoco Remedies
Rev 3Mar 2

How does Indoco Remedies rank in Pharmaceuticals & Biotechnology?

Compare Indoco Remedies against every Pharmaceuticals & Biotechnology company (Q2 FY24) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →